Find a Trial

Trial Summary


Protocol No.CTO-CLR-15-03
StatusOPEN TO ACCRUAL
Principal InvestigatorSayar, Hamid
ScopeNational
PhasePhase I/II
Age GroupAdult
TitleA Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
DescriptionPhase 1/2 study to determine safety, tolerability, pharmacokinetics and activity of K0706.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Male or female aged greater than or equal to 18 years of age.
  • No major surgery, as determined by the Investigator, within 4 weeks of IMP administration.
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesLeukemia, other
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632
    Email: iutrials@iu.edu